Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PBZ vs ACTIDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PBZ (phenylbutazone) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It also has uricosuric effects.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
FDA-approved for relief of acute gouty arthritis and ankylosing spondylitis,Off-label for rheumatoid arthritis and other inflammatory conditions (rarely used due to toxicity)
Allergic rhinitis,Allergic conjunctivitis,Urticaria,Angioedema
25-50 mg orally every 4-6 hours as needed; not to exceed 300 mg/day. For severe allergies: 25 mg intramuscularly or intravenously every 4-6 hours.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
Terminal elimination half-life: 8-12 hours in adults; prolonged in renal impairment (up to 24 hours).
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Primarily hepatic via CYP450 enzymes (including CYP2C9), with renal excretion of metabolites.
Hepatic via CYP450 isoenzymes (primarily CYP3A4 and CYP2D6); undergoes N-demethylation and N-oxidation.
Renal excretion of unchanged drug (approximately 70-80%) with the remainder as metabolites. Biliary/fecal excretion accounts for <5%.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
95-98% bound to albumin and alpha-1-acid glycoprotein.
Approximately 90% bound to plasma proteins, primarily albumin.
2-3 L/kg, indicating extensive tissue distribution.
2.5-4.0 L/kg, indicating extensive tissue distribution.
Oral: 60-70% (first-pass metabolism reduces absolute bioavailability).
Oral bioavailability is approximately 50-60% due to first-pass metabolism.
No specific guidelines available; use with caution in severe renal impairment (GFR <10 m L/min) due to potential accumulation. Consider dose reduction or increased dosing interval.
GFR 10-50 m L/min: 2.5 mg every 6-8 hours; GFR <10 m L/min: 2.5 mg every 8-12 hours.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor for sedation; Child-Pugh Class C: avoid use due to risk of hepatic encephalopathy or reduce dose by 75%.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Children 2-6 years: 5 mg orally every 4-6 hours, not to exceed 30 mg/day; Children 6-12 years: 10-15 mg orally every 4-6 hours, not to exceed 60 mg/day; Children >12 years: adult dose.
Children 2-5 years: 1.25 mg orally every 4-6 hours (max 5 mg/day); Children 6-12 years: 1.25-2.5 mg every 4-6 hours (max 7.5 mg/day).
Start at 10 mg orally every 6-8 hours; titrate cautiously due to increased sensitivity (sedation, dizziness, anticholinergic effects). Avoid if possible; consider alternative antihistamine with lower anticholinergic burden.
Initiate at 1.25 mg orally every 6-8 hours; maximum 5 mg per day due to increased risk of anticholinergic effects and renal impairment.
Risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation; risk of cardiovascular thrombotic events; use is contraindicated for perioperative pain in CABG surgery.
None
Risk of agranulocytosis, aplastic anemia, and other blood dyscrasias; GI toxicity; cardiovascular events; renal toxicity; hepatic effects; use only when other NSAIDs are ineffective and for short durations; contraindicated in patients with aspirin-sensitive asthma.
May cause drowsiness and impair mental alertness,Avoid alcohol and other CNS depressants,Use with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, or urinary retention,Elderly patients are more susceptible to anticholinergic effects
History of hypersensitivity to NSAIDs; active GI bleeding or peptic ulcer disease; severe hepatic or renal impairment; known coronary artery bypass graft (CABG) surgery; blood dyscrasias.
Hypersensitivity to any component,Concurrent use with monoamine oxidase inhibitors
Avoid concurrent use of alcohol and other CNS depressants. No specific food restrictions, but grapefruit juice has not been studied with this drug. Administer with food if gastrointestinal discomfort occurs.
No specific food interactions, but taking with food may reduce GI side effects. Alcohol should be strictly avoided due to additive CNS depression. Grapefruit juice is not documented to interact.
PBZ (Piroxicam) is a nonsteroidal anti-inflammatory drug (NSAID). First trimester: Avoid use; associated with increased risk of miscarriage and congenital malformations (e.g., cardiac defects) due to prostaglandin synthesis inhibition. Second trimester: Use only if clearly needed; potential for oligohydramnios and fetal renal dysfunction. Third trimester: Contraindicated; risk of premature closure of ductus arteriosus, persistent pulmonary hypertension, and oligohydramnios.
First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergic effects may cause neonatal tachycardia, irritability, and withdrawal symptoms if used near term.
PBZ is excreted into breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.01-0.2. Due to potential adverse effects on infant cardiovascular and renal systems (e.g., platelet dysfunction, renal impairment), use is generally not recommended. Consider alternative analgesics with more established safety profiles.
Excretion into breast milk likely but negligible amounts; no adverse effects reported in infants. M/P ratio not established. Considered compatible with breastfeeding; monitor for sedation or irritability in neonate.
Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered clearance) may require dose adjustments. However, due to teratogenic risks, PBZ is generally avoided during pregnancy. If use is unavoidable, use the lowest effective dose for the shortest duration, with careful monitoring.
No specific dose adjustments required in pregnancy; however, use lowest effective dose due to potential anticholinergic effects. Pharmacokinetics may be altered (increased volume of distribution), but no dose adjustment recommended.
PBZ (tripelennamine) is a first-generation antihistamine with sedative properties. It is used primarily for allergic conditions and pruritus. Avoid in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention. Monitor for anticholinergic effects (dry mouth, blurred vision, constipation). May cause paradoxical excitation in children. Dose reduction needed in hepatic impairment.
ACTIDIL (triprolidine) is a first-generation antihistamine with sedative properties. Use cautiously in elderly due to risk of confusion, urinary retention, and falls. Avoid in patients with narrow-angle glaucoma, BPH, or asthma. Administer with food if GI upset occurs. Onset of action is 30-60 minutes; duration 4-6 hours.
Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause drowsiness.,Avoid alcohol and other CNS depressants to prevent increased sedation.,Take with food or milk to reduce stomach upset.,Do not crush or chew extended-release tablets; swallow whole.,Contact your doctor if you experience blurred vision, difficulty urinating, or severe constipation.,May cause dry mouth; use sugar-free gum or candy to alleviate.,Store at room temperature away from moisture and heat.,Keep out of reach of children; overdose may cause hallucinations or seizures.
Do not drive or operate heavy machinery until you know how this medication affects you; it can cause drowsiness.,Avoid alcohol and other CNS depressants, as they may increase sedation.,Take exactly as prescribed; do not exceed recommended dose.,If you miss a dose, skip it; do not double the next dose.,Notify your doctor if you experience blurred vision, difficulty urinating, or severe drowsiness.,Do not use for prolonged periods without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PBZ vs ACTIDIL, answered by our medical review team.
PBZ is a Antihistamine that works by PBZ (phenylbutazone) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It also has uricosuric effects.. ACTIDIL is a Antihistamine that works by H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PBZ and ACTIDIL depend on the specific clinical indication. These are both Antihistamine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PBZ is: 25-50 mg orally every 4-6 hours as needed; not to exceed 300 mg/day. For severe allergies: 25 mg intramuscularly or intravenously every 4-6 hours.. The standard adult dose of ACTIDIL is: 2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PBZ and ACTIDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PBZ is classified as Category C. PBZ (Piroxicam) is a nonsteroidal anti-inflammatory drug (NSAID). First trimester: Avoid use; associated with increased risk of miscarriage and congenital malformations (e.g., card. ACTIDIL is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.